RUMINATIVE ANNOUNCEMENT ON NANOPARTICLES AND MONONUCLEAR PHAGOCYTIC SYSTEM
Abstract
The aim of the present review provides the relationship between therapeutic nanoparticles and mononuclear phagocytic system. Reticuloendothelial system (RES) represents a group of cells having the ability to take up and sequester inert particles and vital dyes. This includes macrophages and macrophage precursors, specialized endothelial cell lining the sinusoids of the liver, spleen and bone marrow, and the reticular cell of the lymphatic tissue (macrophages) and of the bone morrow (fibroblast). Nanoparticles are rapidly sequestered and retained by the organs comprising of the reticuloendothelial system (RES), mainly the liver, spleen and the bone marrow. Thus, targeting of the nanoparticles to the reticuloendothelial system (RES) is much simpler than to any other organ. In the liver, the particles are mainly retained by the scavenging periportal and midzonal Kupffer cells, while the hepatocytes and liver endothelial cells may play a secondary role under special pathophysiological conditions or for special physic- chemical characteristics of particles. The clearance of conventional nanoparticles has been proposed to occur by uptake of the nanoparticles by the reticuloendothelial system (RES). The mononuclear phagocytic system uptake of nanoparticles results in their rapid removal from the blood and accumulation in tissues involved in the RES, such as the liver and spleen. Uptake by the RES usually results in irreversible sequestering of the encapsulated drug in the RES, were it can be degraded. In addition, the uptake of the nanoparticles by the RES may result in acute impairment of the mononuclear phagocytic system and toxicity. Sterically stabilized nanoparticles, such as STEALTH nanoparticles, prolong the duration of exposure of the encapsulated nanoparticles in the systemic circulation. The presence of the PEG coating on the outside of the nanoparticles does not prevent uptake by the reticuloendothelial system, but simply reduces the rate of uptake.
Keywords:
Nanoparticles, Mononuclear Phagocytic System, Reticuloendothelial System, STEALTH nanoparticlesDOI
https://doi.org/10.25004/IJPSDR.2015.070201References
2. http:/ / www. Britannica.com/bps/user- profile/4419/the-editors-of-encyclopedia-Britannica.
3. Knight J, Nigam Y. The Lymphatic System Part 3 – The Lymphatic System and Immunity. NT 2008; 104(15): 22-23.
4. Deodhar MS, Shirode AR, Kadam VJ. High Performance Nanoparticles Fluid Suspensions (Nanofluide): A Future of Pharmaceutical Nanotechnology. International Journal of Pharmaceutical Science and Drug Research 2014; 6(4): 263-270.
5. Chandrababu D, Patel HB, Patel HL, Dimeshbhai MJ. A review on pharmaceutical nanotechnology. Asian Journal of Pharmacy and Life Science 2012; 2(2): 324- 338.
6. Kupffer cell. From Wikipedia, the Free Encyclopedia.
7. Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne M. CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens. Cell 2006; 124: 915-927.
8. Romberg B, Hennink WE, Storm G. Sheddable Coatings for Long Circulating Nanoparticles. Pharm Res. 2008; 25(1): 55-71.
9. Talegaonkar S, Tariq M, Alabood RM. Design and Development of O/W Nanoemulsion for the Transdermal Delivery of Ondansetron. Bulletin of Pharmaceutical Research 2011; 1(3):18-30.
10. Yadav AK, Sharma A, Saxena S, Kesarwani A. Mouth Dissolving Tablets: General Overview and Formulation Aspects. Bulletin of Pharmaceutical Research 2014; 4(1): 43-57.
11. Mohanraj VJ, Chen Y. Nanoparticles - A Review. Tropical Journal of Pharmaceutical Research 2006; 5(1): 561-573.
12. Kreuter J. Coating of Nanoparticles with Surfactants: Targeting Versus Prolonged Circulation. Targeting of Drugs 6, NATO ASI Series. 1998; 300: 253-261.
13. Moghimi SM, Hunter AC, Murray JC. Long-Circulating and Target-Specific Nanoparticles: Theory to Practice. Pharmacological Reviews 2001; 53(2): 283-318.
14. Wei W, Jiang X. Wei W, Jiang X. Functional nanoparticles for bioanalysis, nanomedicine, and bioelectronic devices. Volume 2, ACS Symposium Series, Vol. 1113, Chapter 2, pp. 27–36. 4, 5.
15. Lobatto ME, Fuster V, Fayad ZA, Mulder WJM. Perspectives and Opportunities for Nano Medicine in the Management of Atherosclerosis. Nature Reviews Drug Discovery 2011; 10(11): 835-852.
16. Woodle MC, Engbers CM, Zalipsky S. New Amphipatic Polymer-Lipid Conjugates Forming Long-Circulating Reticuloendothelial System-Evading Liposomes. Bioconjug Chem 1994; 5(6): 493-496.
17. Salmaso S, Caliceti P. Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers. Journal of Drug Delivery 2013; Article ID 374252: 19 pages.
18. Roser M, Fischer D, Kissel T. Surface-Modified Biodegradable Albumin Nano-and Microspheres. II: effect of surface charges on in vitro phagocytosis and Biodistribution in rats. European Journal of Pharmaceutics and Biopharmaceutics 1998: 46(3); 255-263.
19. Garcia KP, Zarschler K, Barbaro L, Barreto JA, O’Malley W, Spiccia L, Stepphan H, Graham B. Zwitterionic Coated “Stealth” Nano Particles for Biomedical Applications: Recent Advance in Countering Biomolecular Corona Formation and Uptake by the Mononuclear Phagocyte System. Small 2014; 10(13): 2516-2529.
20. Storm G, Belliot SO, Daemen T, Lasic DD. Surface Modification of Nanoparticles to Oppose Uptake by the Mononuclear Phagocyte System. Advanced Drug Delivery 1995; 17(1): 31-48.
21. Mahapatro A, Singh DK. Biodegradable Nanoparticles are Excellent Vehicle for Site Directed In-vivo Delivery of Drugs and Vaccines. Journal of Nano biotechnology 2011; 9: 55.
22. Song G, Petschauer JS, Madden AJ, Zamboni WC. Nanoparticles and the Mononuclear Phagocyte System: Pharmacokinetics and Applications for Inflammatory Diseases. Current Rheumatology Reviews 2014; 10(1): 22-34.
23. Mortimer GM, Butcher NJ, Musumeci AW, Deng ZJ, Martin DJ, Minchin RF. Cryptic Epitopes of Albumin Determine Mononuclear Phagocyte System Clearance of Nanomaterials. ACS Nano 2014; 8(4): 3357–3366.
24. Caron WP, Rawal S, Song G, Kumar P, Lay JC, Zamboni WC. Bidirectional Interaction between Nanoparticles and Cells of the Mononuclear Phagocytic System. Handbook of Immunological Properties of Engineered Nanomaterials 2013; 1: 385-416.
Published
Abstract Display: 285 
PDF Downloads: 442 How to Cite
Issue
Section
Copyright (c) 2015 Balasubramanian ., T. Sravanthi, V. Sujitha
This work is licensed under a Creative Commons Attribution 4.0 International License.
